Indivior Share Discussion Threads

[waldron] 26/2/2021 19:13

THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 100 to 110p 110 to 120p 120 to 130p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 130 to 140p 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p Citi target 185p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again December 2020 ends at 108.80p January 2021 ends at 137.35p

[waldron] 20/2/2021 09:21

[United Kingdom] INDIVIOR (INDV) Delayed Quote. Delayed London Stock Exchange - 02/19 04:35:13 pm 127.6 GBX -8.40%

[waldron] 20/2/2021 09:20

THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 100 to 110p 110 to 120p 120 to 130p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 130 to 140p 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p Citi target 185p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again December 2020 ends at 108.80p January 2021 ends at 137.35p February 2021 ends at 128.10p

[baddeal] 19/2/2021 17:39

Slightly surprised at the weakness on the results but guess it's had a good run. Still plenty of upside imo

[waldron] 18/2/2021 16:27

Proactiveinvestors Philip Whiterow 08:34 Thu 18 Feb 2021 Follow Philip on: Investor deep dive Symphony Environmental makes progress in battle against COVID-19 read more > viewIndivior PLC Indivior in red after legal settlements take toll Losses for the year were US$173mln with a US$14mln deficit in the final three months Indivior PLC - Suboxone's market share is falling rapidly Indivior PLC (LON:INDV) posted an improvement in sales in the final quarter of 2020 as Sublocade, its injectable, extended-release opioid dependency treatment, picked up momentum. The drug group is trying to build sales of Sublocade to offset a steady decline by its predecessor Suboxone, which has now come off patent. Revenues for the year to end-December fell 18% to US$647mln though there was a 39% jump in the final quarter as sales of Sublocade rose 18%. Losses for the year were US$173mln with a US$14mln deficit in the final three months. During the year, Indivior settled outstanding legal cases with the US Department of Justice and former parent Reckitt Benckiser and Indivior took one-off charges of US$244mln in the 2020 numbers. Mark Crossley, chief executive, said that given the problems related to the coronavirus pandemic he was 'delighted' with the numbers. “Critically, we materially de-risked the business with resolution of the DOJ and RB matters and we took decisive strategic alignment actions which place Indivior on a clear path towards realizing the transformational potential of Sublocade. “Accelerating the growth of Sublocade remains the biggest potential driver of value creation.“ Indivior’s base case assumptions for 2021 are for net revenues to rise to US$625mln with Sublocade net revenues of between US185mln and $210mln (2020: US$130mln).

[gregmorg] 18/2/2021 13:57

Well, the preliminary statement today appeared steady but unexciting and I am afraid it did very little for me. Nevertheless I found the upbeat webcast rather more reassuring. It gave a very positive message for the medium/ long term without a doubt. Shorter term I just don't know as I am unsure what will drive it. So with all its complexities I will await events.

[la forge] 05/2/2021 17:34

04 February 2021 Indivior to Announce FY 2020 Results and Host a Presentation on February 18(th) Slough, UK, and Richmond, VA, February 4, 2021 - Indivior PLC (LON: INDV) today announced that it will release its FY 2020 results on February 18th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com . Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 12:00 GMT (7:00 a.m. U.S. Eastern) on February 18th. Access to the Live Webcast Presentation The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link is Https://edge.media-server.com/mmc/p/23dggtiy . Participants may access the presentation telephonically : -- US participants 1-646-741-3167 -- International participants [phone] Please reference confirmation ID 3290938. A replay of the presentation will be available at www.indivior.com .

[la forge] 05/2/2021 17:32

Upcoming events on INDIVIOR February/18/2021 FY 2020 Earnings Release

[waldron] 29/1/2021 21:40

THE WISH LIST GIVING BOXES,Supports and Resistences to determine channels and trends together with broker targets which might of course make you smile or and smirk 100 to 110p 110 to 120p 120 to 130p 130 to 140p$$$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$ 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p Citi target 185p 190 to 200p Jefferies target 200p Https://www.marketscreener.com/INDIVIOR-19344116/ DECEMBER END 2019 GIVES 39p which puts us into the 30 to 40p BOX again December 2020 ends at 108.80p January 2021 ends at 137.35p

[waldron] 29/1/2021 21:36

[United Kingdom] INDIVIOR (INDV) Real-time Estimate Quote. Real-time Estimate CHI-X - 01/29 04:30:00 pm 137.35 GBX +2.12%

[baddeal] 26/1/2021 14:02

I prefer the Numis analysts view and tp......INDIVIOR (BUY, 320p) RB indemnity resolved. Indivior last night announced that it had settled with former parent Reckitt Benckiser, and will pay RB $50m over 5-years. This is clearly a welcome relief since the initial claim of $1.4bn raised concerns over the ongoing liquidity of the company. Indivior has also released RB from any indemnity claims it may have had. Indivior is now in a very strong position to build on the encouraging end to FY20 with full results expected to be published on 18-Feb. In our view, the shares remain very cheap on 5x EV/EBITDA with the prospects for the business improving significant given the expected expansion of the prescriber base given changes to prior restrictions.

[sarkasm] 26/1/2021 10:38

Michele Maatouk Sharecast News 26 Jan, 2021 09:52 26 Jan, 2021 10:12 Operational strength to drive story at Indivior, Citi says The removal of the Reckitt Benckiser overhang should allow operational strength to drive the story at opioid addiction treatment maker Indivior, Citi said on Tuesday. Indivior 144.50p 09:30 26/01/21 Indivior shares were sharply higher after Reckitt Benckiser said late on Monday that it will withdraw a $1.4bn claim against the company. Indivior has agreed to pay the consumer goods giant $50m to end the legal battle related to a US probe into opioid addition. Citi said that after a long period of litigation dominating the debate, firstly with Department of Justice indictment and more recently with a claim from Reckitt, the stock should now benefit from "the demonstrated progress in the last year". The bank said the rollout of Sublocade is regaining momentum after a Covid-related stall, while Suboxone film continues its "resilient" performance against branded and generic competitors. In addition, Perseris has similarly staged a recovery from Covid-related rollout issues, Citi said. It also expects the recent UK Supreme Court ruling on buprenorphine prescribing to provide a further tailwind to market volumes in 2021. The bank reiterated its ‘buy’ rating on the shares and lifted the price target to 185p. "Given the recent operational progress, we expect the shares to recover today to at least the highest level after the DoJ settlement and before the RB claim was announced in November," it said. At 0950 GMT, Indivior shares were up 12.9% at 144.40p.

[imnotspartacus] 26/1/2021 09:48

The weekly chart starting to look tasty, breakout on the cards! I've got the next resistance at 200p.

[waldron] 26/1/2021 09:36

wondering what next resistence level might be

[genierub] 26/1/2021 09:13

Hardly. Just levelling out before the next push. Its getting ready to move up.

[justtrying1] 26/1/2021 08:56

Dropping back

[genierub] 26/1/2021 08:32

Back over 400p we go. Been a long time coming. An absolute gem of an RNS last night.

[waldron] 26/1/2021 08:32

Real-time Estimate Quote. Real-time Estimate CHI-X - 01/26 03:31:25 am 144.45 GBX +12.94% Looking good Billyray

[steeplejack] 26/1/2021 08:15

Yes,couldn't agree more,a period without a litigation debacle coming out of the mist would be most welcome.I sold out when the RCOL legal filing emerged and then felt obliged to buy back in at a higher price a couple of weeks back!Think I'll just confine the current holding to long term locker ....he says hopefully.

[gregmorg] 25/1/2021 18:02

well the after hours RNS at least removes the Reckitt indemnity uncertainty. Itcould have hung around and depressed the share price for years. The $50m settlement payable over five years is a result just to put it behind u. How about a decent run with fewer banana skins. They can get tiresome!

[imnotspartacus] 19/1/2021 17:55

Definitely a good day today, moving up nicely!

[maywillow] 19/1/2021 17:31

Iain Gilbert Sharecast News 19 Jan, 2021 16:46 19 Jan, 2021 16:46 , Indivior Jefferies included drugs manufacturer Indivior on their latest quarterly list of 15 key buy ideas in the UK small and mid-cap space. Analyst Harry Sephton argued that the company's shares were not pricing in "sufficient upside" for Sublocade, the company's treatment for medium-to-severe opioid addiction. He estimated financial markets were pricing in peak sales below $250.0m for Sublocade, projections that he believed were "too conservative". To back up his case, Sephton pointed out how sales of Sublocade were already running at an annual pace of approximately $150.0m and continuing to grow "incrementally". Furthermore, the patient population was growing at a double-digit pace and proprietary surveys showed that doctors were anticipating a significant uptake over the next five years. Covid-19 restrictions had also been hampering sales and marketing activity for Sublocade, but that was expected to change. Sephton had a 'buy' recommendation and 180.0p target price on Indivior's shares, using a sum-of-the-parts net present valuation method and a 10% weighted average cost of capital to derive the latter.